Methenamine Hippurate (branded as Altaromin©) have gained marketing approval in France
27 juni, 07:30
Methenamine Hippurate (branded as Altaromin©) have gained marketing approval in France
EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle under the EQL owned brand Altaromin©. Launch is planned for early 2026, subject to reimbursement approvals.
Altaromin© is the only methenamine hippurate product registered in France. French patients with recurring urinary tract infections will now for the first time have access to a non-inferior alternative to antibiotics. An alternative which doesn’t increase the risk to develop antibiotic-resistant bacteria.
About Altaromin®
Altaromin® is taken as a tablet containing 1g of the antiseptic substance methenamine hippurate. It is indicated as a prophylactic treatment for patients, mainly women, troubled by recurring urinary tract infections. As a prophylactic treatment Altaromin® is taken twice daily by the patient even when the patient isn’t showing any symptoms of an infection.
About EQL
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
About Laboratoires Majorelle
Laboratoires Majorelle is a well-known leading pharmaceutical company in France specialized in women’s health with very good relations with Healthcare Authorities and specialists, as well as strong capabilities in sales and marketing.
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Ämnen i artikeln
Methenamine Hippurate (branded as Altaromin©) have gained marketing approval in France
27 juni, 07:30
Methenamine Hippurate (branded as Altaromin©) have gained marketing approval in France
EQL's key product methenamine hippurate has now gained marketing approval by the Health Authorities in France, where it is to be provided to patients by EQL's license partner Laboratoires Majorelle under the EQL owned brand Altaromin©. Launch is planned for early 2026, subject to reimbursement approvals.
Altaromin© is the only methenamine hippurate product registered in France. French patients with recurring urinary tract infections will now for the first time have access to a non-inferior alternative to antibiotics. An alternative which doesn’t increase the risk to develop antibiotic-resistant bacteria.
About Altaromin®
Altaromin® is taken as a tablet containing 1g of the antiseptic substance methenamine hippurate. It is indicated as a prophylactic treatment for patients, mainly women, troubled by recurring urinary tract infections. As a prophylactic treatment Altaromin® is taken twice daily by the patient even when the patient isn’t showing any symptoms of an infection.
About EQL
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
About Laboratoires Majorelle
Laboratoires Majorelle is a well-known leading pharmaceutical company in France specialized in women’s health with very good relations with Healthcare Authorities and specialists, as well as strong capabilities in sales and marketing.
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.
For more information contact:
Axel Schörling,
CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com
Web: www.eqlpharma.com
Ämnen i artikeln
Rapportperioden
-992x558.jpg&w=3840&q=75)
Plejd
Rapportperioden
Plejd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
